Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Grainne who wrote (114)	8/16/1998 11:50:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 666

Christine, as I said, this is not an area I am that familiar with. The approach does sound logical, but it has been around for a while and it's not clear what's better or different about CLTR's TAP program. On why the work with scientists from Belgium (the Catholic university has good reputation), I am not sure, but it seems to me the old, pre-spin off, Coulter had some relationship with them. It's my impression Coulter Pharmaceuticals was spun off to collect "loose" therapeutic projects, with Bexxar (B-1, as it was called then) at the center. PB